: SpringWorks Therapeutics’ stock jumps after FDA approves first treatment for rare type of aggressive tumors

SpringWorks shares jumped early Tuesday after regulatory approval for tumor treatment

Previous post Economic Report: U.S. home prices climb for seven month in a row to a record high, Case-Shiller says
Next post Fed’s Waller expresses confidence that policy is in the right place to bring down inflation